Cork-based biopharmaceutical company Evumed has announced a multi-million-euro investment at Cork Airport Business Park, establishing its European headquarters at the location and creating 30 high-value jobs across quality, regulatory, supply chain, finance, and support functions during 2026, according to CorkBeo.

Founded last year, Evumed specialises in high-quality, affordable generic, branded, and biologic medicines, with operations spanning research and development and manufacturing. The Cork Airport Business Park location will serve as the company's base for European growth.

Colm Moynihan, president of Evumed, said: "Cork Airport Business Park's exceptional global connectivity and modern infrastructure, coupled with Cork's position as a global hub for pharmaceutical manufacturing and innovation, offer Evumed the ideal location to grow as we aim to develop and deliver generic, branded, and biologic medicines and bring innovation and accessibility together to improve lives."

Cork Airport Business Park, which marked its 25th anniversary in 2025, is home to a significant concentration of major international companies including Amazon, IBM, McKesson, GSK, Emerson, and Red Hat, reinforcing its standing as one of Ireland's most strategically positioned business locations for pharmaceutical and technology investment.

The Evumed deal was completed by letting agents Knight Frank, which is also in discussions with three global companies regarding potential tenancies at the park, indicating continued strong international demand for Cork-based premises.

The investment reinforces Cork's reputation as a leading European destination for pharmaceutical and biopharmaceutical companies seeking access to skilled talent, established industry networks, and strong global connectivity.

Read the full report for further detail on Evumed's Cork investment and European headquarters plans.